Response to standard of care antiviral treatment in patients with HCV liver cirrhosis - a systematic review

Journal of Gastrointestinal and Liver Diseases

Volumn 20, Issue 3, 2011, Pages 293-298

  Bota, Simona ^a   Sporea, Ioan ^a   Popescu, Alina ^a   Sirli, Roxana ^a   Neghina, Adriana Maria ^a   Danila, Mirela ^a   Strain, Mihnea ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

HCV; Hepatitis C; Liver cirrhosis; Pegylated interferon; Ribavirin; Sustained virological response; Systematic review

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGUS VARICES; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; PORTAL HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUSTAINED VIROLOGICAL RESPONSE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS DETECTION;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; QUALITY-ADJUSTED LIFE YEARS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 80053535445     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Global surveillance and control of Hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 34-35.
2. Touzet S, Kraemer L, Colin C, et al. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Cooperative Research). Eur J Gastroenterol Hepatol 2000; 12: 667-678.
3. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-2441.
4. Asian Pacifc Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, et al. Asian Pacifc Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22: 615-633.
5. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-1310.
6. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999;29:1311-1316.
7. Gane E. The natural history and outcome of liver transplantion in hepatitis C virus infected recipients. Liver Transpl 2003; 9: S28-S34.
8. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV infected liver transplant recipients. Hepatology 2002; 36: 202-210.
9. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
10. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
11. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C (AASLD practice guideline). Hepatology 2004; 39: 1147-1171.
12. Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002; 36: S185-S194.
13. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with hepatitis C and advanced fbrosis. Ann Intern Med 2007; 147: 677-684.
14. Syed E, Rahbin N, Weiland O, et al. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh A liver cirrhosis. Scand J Gastroenterol 2008; 43: 1378-1386.
15. Fernandez-Rodriguez CM, Alonso S, Martinez SM, et al. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol 2010; 105: 2164-2172.
16. Butt AS, Mumtaz K, Aqeel I, Shah HA, Hamid S, Jafri W. Sustained virological response to pegylated interferon and ribavirin in patients with genotype 3 HCV cirrhosis. Trop Gastroenterol 2009; 30; 207-212.
17. Giannini EG, Basso M, Savarino V, Picciotto A. Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. J Intern Med 2009; 266: 537-546.
18. Helbling B, Jochum W, Stamenic I, et al. HCV-related advanced fbrosis/cirrhosis: randomized controlled trial of pegylated interferon alfa 2a and rivabirin. J Viral Hepat 2006; 13: 762-769.
19. Iacobellis A, Siciliano M, Annicchiarico BE, et al. Sustained virological response following standard antiviral therapy in decompensed HCV-infected cirrhotic patients. Aliment Pharmacol Ther 2009; 30: 146-153.
20. Roff L, Colloredo G, Pioltelli P, et al. Pegylated interferon alfa 2b plus ribavirin: an effcacious and well-tolered treatment regimen for patients with hepatitis C virus related histologicaly proven cirrhosis. Antivir Ther 2008; 13: 663-673.
21. Sood A, Midha V, Sood N, Bansal M. Pegylated interferon alfa 2b and ribavirin in patients with HCV-related cirrhosis. Indian J Gastroenterol 2006; 25: 283-285.
22. Tekin F, Gunsar F, Karasu Z, Akarca U, Ersoz G. Safety, tolerability and effcacy of pegylated-interferon alfa 2a plus ribavirin in HCV-related decompensed cirrhotics. Aliment Pharmacol Ther 2008; 27: 1081-1085.
23. Moreno Planas JM, Rubio González E, Boullosa Graña E, et al. Effectiveness of pegylated interferon and ribavirin in patients with liver HCV cirrhosis. Transplant Proc 2005; 37: 1482-1483.
24. Di Marco V, Almasio PL, Ferraro D, et al. Peginterferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007; 47: 484-491.
25. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alpha-2b in chronic hepatitis C: sistematyc review of randomized trials. Hepatology 2010; 51: 1176-1184.
26. Saab S, Hunt DR, Stone MA, McClune A, Tong MJ. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl 2010; 16: 748-759.
27. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL 28B predicts hepatitis C treatment-induced viral clearence. Nature 2009; 461: 399-401.
28. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345.
29. Grebely J, Petoumenos K, Hellard M, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010; 52: 1216-1224.
30. de Rueda PM, López-Nevot MA, Sáenz-López P, et al. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. Am J Gastroenterol 2011;106:1246-1254. 31.
31. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.
32. Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011; 8: 257-264.
33. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
34. Smith LS, Nelson M, Naik S, Woten J. Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother 2011; 45: 639-648.
35. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
36. Dusheiko GM, Fried MW, Reddy R, et al. Telaprevir in combination with PegInterferon alfa-2a and Ribavirin increased sustained virological response rates in treatment-naive patients regardless of race or ethnicity. J Hepatol 2011; 54(Suppl 1): S167.
37. Marcellin P, Jacobson IM, Zeuzem S, et al. Telaprevir in combination with PegInterferon alfa-2a and Ribavirin: Analysis of pre-defned subpopulations in the phase 3 ADVANCE trial. J Hepatol 2011; 54 (Suppl 1): S183.
38. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
39. Zeuzem S, Vierling JM, Esteban R, et al. Predictors of sustained virologic response among genotype 1 previous non-responders and relapsers to PegInterferon/Ribavirin when re-treated with Boceprevir plus PegInterferon alfa-2b/Ribavirin. J Hepatol 2011; 54 (Suppl 1): S198.
40. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
41. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011; 140: 459-468.
42. Jacobson IM, Catlett I, Marcellin P, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. J Hepatol 2011; 54 (Suppl 1): S542.
43. Poordad F, Bronowicki JP, Gordon SC, et al. IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with Boceprevir (BOC) combination therapy. J Hepatol 2011; 54 (Suppl 1): S6.